Viatris Inc
NASDAQ:VTRS

Watchlist Manager
Viatris Inc Logo
Viatris Inc
NASDAQ:VTRS
Watchlist
Price: 12.37 USD -0.72% Market Closed
Market Cap: 14.2B USD

Viatris Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Viatris Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Viatris Inc
NASDAQ:VTRS
Operating Income
$1.3B
CAGR 3-Years
-24%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$16.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
19%
Pfizer Inc
NYSE:PFE
Operating Income
$18.3B
CAGR 3-Years
-23%
CAGR 5-Years
12%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Operating Income
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Operating Income
$26.4B
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
22%
No Stocks Found

Viatris Inc
Glance View

In the bustling realm of pharmaceutical giants, Viatris Inc. has carved out a distinctive path since its inception in November 2020, born from the merger of Mylan N.V. and Pfizer’s Upjohn division. This union forged a new entity poised to leverage a vast portfolio of iconic brands and generic drugs. At its core, Viatris operates on a diversified business model, producing and distributing therapeutic solutions that range from well-known branded medications to complex generics and over-the-counter (OTC) products. With operations spanning across the globe, the company ensures the delivery of critical healthcare solutions to millions, focusing on accessibility and affordability. This global approach not only enhances its revenue streams but also strengthens its market resilience against regional disruptions. Strategically, Viatris has placed a hefty emphasis on integrating and optimizing supply chains, thereby maximizing operational efficiencies and profit margins. By successfully blending the robust generic drug capabilities of Mylan with the established brand strength of Pfizer’s Upjohn, Viatris is well-positioned to capture and sustain market share across diverse therapeutic categories. Additionally, Viatris invests heavily in research and development to expand its pipeline of complex generics and biosimilars, potentially paving the way for future growth and innovation. This strategic alignment allows the company to cater to a broad spectrum of patient needs and healthcare systems worldwide, making it a formidable player in the pharmaceutical industry.

VTRS Intrinsic Value
31.85 USD
Undervaluation 61%
Intrinsic Value
Price

See Also

What is Viatris Inc's Operating Income?
Operating Income
1.3B USD

Based on the financial report for Sep 30, 2025, Viatris Inc's Operating Income amounts to 1.3B USD.

What is Viatris Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-3%

Over the last year, the Operating Income growth was -2%. The average annual Operating Income growth rates for Viatris Inc have been -24% over the past three years , -7% over the past five years , and -3% over the past ten years .

Back to Top